InsidersTradesSigma
Total declarations
Companies
▲ Purchases (4 ops.)
▼ Sales (0 ops.)
Browse the detailed record of transactions filed by Thorp Clay, Director. Director active across 3 companies, notably PhaseBio Pharmaceuticals Inc. Aggregated, 6 reports have been logged. Total volume traded: €129k. The latest transaction was filed on 16 May 2022 (Acquisition). Regulator: SEC (Form 4). The full history is free.
Declarations6 total
€57,68921,802 shares@ €2.64674.6% of flow
Common Stock
SEC:0000899243-22-018491:0·
Ideal exit: 10 Feb 2023 (T+270)
€19,6513,000 shares@ €6.550425.4% of flow
Common Stock
SEC:0000899243-22-012485:0·
Ideal exit: 23 Dec 2022 (T+270)
1,254,335 shares
Common Stock
SEC:0000899243-22-001658:0·
1,254,335 shares
Common Stock
SEC:0000899243-22-001658·
€25,63410,000 shares@ €2.5634100.0% of flow
Common Stock
SEC:0001169245-21-000080·
Ideal exit: 15 May 2022 (T+270)
€25,63410,000 shares@ €2.563450.0% of flow
Common Stock
SEC:0001169245-21-000080:0·
Ideal exit: 15 May 2022 (T+270)
6 of 6 declarations
About Thorp Clay
Clay Thorp is a Board Member at PhaseBio Pharmaceuticals Inc and Vigil Neuroscience, Inc. He plays a key role in corporate governance, bringing his expertise in strategy and business development. His commitment to innovation is essential for guiding decisions within the boards.
